Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 254.35 Thousand USD | -0.05% |
| 2022 | 254.49 Thousand USD | 11.9% |
| 2021 | 227.43 Thousand USD | -4.4% |
| 2020 | 237.9 Thousand USD | -1.95% |
| 2019 | 242.63 Thousand USD | -41.75% |
| 2018 | 416.53 Thousand USD | -11.61% |
| 2017 | 471.22 Thousand USD | -5.26% |
| 2016 | 497.39 Thousand USD | -18.48% |
| 2015 | 610.16 Thousand USD | 6.08% |
| 2014 | 575.17 Thousand USD | 138.66% |
| 2013 | 241 Thousand USD | 17.47% |
| 2012 | 205.15 Thousand USD | 44.46% |
| 2011 | 142.01 Thousand USD | -19.02% |
| 2010 | 175.36 Thousand USD | -5.34% |
| 2009 | 185.26 Thousand USD | -11.77% |
| 2008 | 209.97 Thousand USD | 95.1% |
| 2007 | 107.62 Thousand USD | 34.96% |
| 2006 | 79.74 Thousand USD | 46.1% |
| 2005 | 54.58 Thousand USD | 7.03% |
| 2004 | 50.99 Thousand USD | -35.59% |
| 2003 | 79.18 Thousand USD | 23.44% |
| 2002 | 64.14 Thousand USD | 100.68% |
| 2001 | 31.96 Thousand USD | -43.24% |
| 2000 | 56.31 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 241.02 Thousand USD | -0.62% |
| 2024 Q1 | 242.53 Thousand USD | -4.65% |
| 2023 Q1 | 244.49 Thousand USD | -3.93% |
| 2023 FY | 254.35 Thousand USD | -0.05% |
| 2023 Q2 | 236.64 Thousand USD | -3.21% |
| 2023 Q4 | 254.35 Thousand USD | 21.26% |
| 2023 Q3 | 209.75 Thousand USD | -11.36% |
| 2022 Q3 | 271.13 Thousand USD | 4.04% |
| 2022 Q4 | 254.49 Thousand USD | -6.14% |
| 2022 Q1 | 221.05 Thousand USD | -2.81% |
| 2022 FY | 254.49 Thousand USD | 11.9% |
| 2022 Q2 | 260.61 Thousand USD | 17.89% |
| 2021 Q1 | 257.83 Thousand USD | 8.38% |
| 2021 Q3 | 253.79 Thousand USD | -5.63% |
| 2021 Q4 | 227.43 Thousand USD | -10.39% |
| 2021 FY | 227.43 Thousand USD | -4.4% |
| 2021 Q2 | 268.93 Thousand USD | 4.3% |
| 2020 Q1 | 228.77 Thousand USD | -5.71% |
| 2020 FY | 237.9 Thousand USD | -1.95% |
| 2020 Q4 | 237.9 Thousand USD | -43.53% |
| 2020 Q3 | 421.32 Thousand USD | 94.51% |
| 2020 Q2 | 216.6 Thousand USD | -5.32% |
| 2019 FY | 242.63 Thousand USD | -41.75% |
| 2019 Q1 | 413.25 Thousand USD | -0.79% |
| 2019 Q2 | 397.58 Thousand USD | -3.79% |
| 2019 Q3 | 384.11 Thousand USD | -3.39% |
| 2019 Q4 | 242.63 Thousand USD | -36.83% |
| 2018 Q1 | 453.44 Thousand USD | -3.77% |
| 2018 FY | 416.53 Thousand USD | -11.61% |
| 2018 Q4 | 416.53 Thousand USD | -4.59% |
| 2018 Q3 | 436.58 Thousand USD | 7.11% |
| 2018 Q2 | 407.58 Thousand USD | -10.11% |
| 2017 FY | 471.22 Thousand USD | -5.26% |
| 2017 Q4 | 471.22 Thousand USD | -0.59% |
| 2017 Q3 | 474.01 Thousand USD | 0.18% |
| 2017 Q2 | 473.15 Thousand USD | -5.37% |
| 2017 Q1 | 500.01 Thousand USD | 0.53% |
| 2016 Q4 | 497.39 Thousand USD | -16.46% |
| 2016 Q1 | 621.45 Thousand USD | 1.85% |
| 2016 Q2 | 616.56 Thousand USD | -0.79% |
| 2016 Q3 | 595.36 Thousand USD | -3.44% |
| 2016 FY | 497.39 Thousand USD | -18.48% |
| 2015 Q4 | 610.16 Thousand USD | -5.48% |
| 2015 Q1 | 621.68 Thousand USD | 8.09% |
| 2015 Q2 | 608.48 Thousand USD | -2.12% |
| 2015 FY | 610.16 Thousand USD | 6.08% |
| 2015 Q3 | 645.55 Thousand USD | 6.09% |
| 2014 Q2 | 278.2 Thousand USD | 7.0% |
| 2014 FY | 575.17 Thousand USD | 138.66% |
| 2014 Q3 | 428.95 Thousand USD | 54.18% |
| 2014 Q4 | 575.17 Thousand USD | 34.09% |
| 2014 Q1 | 259.99 Thousand USD | 7.88% |
| 2013 Q2 | 115.01 Thousand USD | -42.7% |
| 2013 Q3 | 101.37 Thousand USD | -11.86% |
| 2013 Q4 | 241 Thousand USD | 137.73% |
| 2013 FY | 241 Thousand USD | 17.47% |
| 2013 Q1 | 200.72 Thousand USD | -2.16% |
| 2012 Q4 | 205.15 Thousand USD | 17.33% |
| 2012 Q1 | 159.31 Thousand USD | 12.18% |
| 2012 Q2 | 171.62 Thousand USD | 7.73% |
| 2012 FY | 205.15 Thousand USD | 44.46% |
| 2012 Q3 | 174.86 Thousand USD | 1.89% |
| 2011 Q4 | 142.01 Thousand USD | 7.55% |
| 2011 Q3 | 132.04 Thousand USD | 32.22% |
| 2011 Q1 | 164.96 Thousand USD | -5.93% |
| 2011 Q2 | 99.86 Thousand USD | -39.46% |
| 2011 FY | 142.01 Thousand USD | -19.02% |
| 2010 FY | 175.36 Thousand USD | -5.34% |
| 2010 Q2 | 174.78 Thousand USD | -3.59% |
| 2010 Q4 | 175.36 Thousand USD | -5.24% |
| 2010 Q3 | 185.06 Thousand USD | 5.88% |
| 2010 Q1 | 181.29 Thousand USD | -2.14% |
| 2009 Q2 | 211.16 Thousand USD | 0.64% |
| 2009 Q4 | 185.26 Thousand USD | -7.73% |
| 2009 FY | 185.26 Thousand USD | -11.77% |
| 2009 Q1 | 209.81 Thousand USD | -0.08% |
| 2009 Q3 | 200.78 Thousand USD | -4.91% |
| 2008 FY | 209.97 Thousand USD | 95.1% |
| 2008 Q4 | 209.97 Thousand USD | -6.38% |
| 2008 Q3 | 224.29 Thousand USD | 32.61% |
| 2008 Q2 | 169.14 Thousand USD | 67.78% |
| 2008 Q1 | 100.81 Thousand USD | -6.33% |
| 2007 Q2 | 94.56 Thousand USD | 1.06% |
| 2007 Q1 | 93.57 Thousand USD | 17.34% |
| 2007 Q4 | 107.62 Thousand USD | 2.21% |
| 2007 FY | 107.62 Thousand USD | 34.96% |
| 2007 Q3 | 105.29 Thousand USD | 11.35% |
| 2006 Q4 | 79.74 Thousand USD | 49.4% |
| 2006 FY | 79.74 Thousand USD | 46.1% |
| 2006 Q3 | 53.37 Thousand USD | -44.76% |
| 2006 Q2 | 96.63 Thousand USD | -0.9% |
| 2006 Q1 | 97.51 Thousand USD | 78.64% |
| 2005 FY | 54.58 Thousand USD | 7.03% |
| 2005 Q4 | 54.58 Thousand USD | -1.43% |
| 2005 Q1 | 67.06 Thousand USD | 31.51% |
| 2005 Q2 | 56.63 Thousand USD | -15.56% |
| 2005 Q3 | 55.37 Thousand USD | -2.22% |
| 2004 Q1 | 77.61 Thousand USD | -1.98% |
| 2004 Q3 | 57.12 Thousand USD | 1.94% |
| 2004 Q2 | 56.03 Thousand USD | -27.8% |
| 2004 FY | 50.99 Thousand USD | -35.59% |
| 2004 Q4 | 50.99 Thousand USD | -10.72% |
| 2003 Q4 | 79.18 Thousand USD | 5.83% |
| 2003 FY | 79.18 Thousand USD | 23.44% |
| 2003 Q1 | 69.26 Thousand USD | 7.98% |
| 2003 Q2 | 68.6 Thousand USD | -0.95% |
| 2003 Q3 | 74.82 Thousand USD | 9.06% |
| 2002 Q4 | 64.14 Thousand USD | -13.52% |
| 2002 Q1 | 29.22 Thousand USD | -8.58% |
| 2002 FY | 64.14 Thousand USD | 100.68% |
| 2002 Q2 | 37.92 Thousand USD | 29.78% |
| 2002 Q3 | 74.17 Thousand USD | 95.58% |
| 2001 Q4 | 31.96 Thousand USD | -32.25% |
| 2001 Q3 | 47.18 Thousand USD | 1.1% |
| 2001 FY | 31.96 Thousand USD | -43.24% |
| 2001 Q1 | 50.94 Thousand USD | -9.54% |
| 2001 Q2 | 46.66 Thousand USD | -8.39% |
| 2000 Q4 | 56.31 Thousand USD | -7.03% |
| 2000 Q3 | 60.57 Thousand USD | 0.0% |
| 2000 FY | 56.31 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Journey Medical Corporation | 10.2 Million USD | 97.508% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 99.771% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | 96.242% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 99.756% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 95.565% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 95.565% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| Safety Shot Inc | 1.86 Million USD | 86.396% |
| Alpha Teknova, Inc. | 11.59 Million USD | 97.806% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 99.213% |
| Bright Green Corporation | - USD | -Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | 99.523% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 99.612% |
| Cosmos Health Inc. | 4.78 Million USD | 94.689% |
| PainReform Ltd. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | 68.589% |
| Embecta Corp. | 152.1 Million USD | 99.833% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 97.816% |
| Procaps Group, S.A. | 96.83 Million USD | 99.737% |
| Theratechnologies Inc. | 6.06 Million USD | 95.807% |
| Harrow Health, Inc. | 10.86 Million USD | 97.659% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | 90.645% |
| Biofrontera Inc. | 10.9 Million USD | 97.668% |
| DURECT Corporation | 2.21 Million USD | 88.538% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 99.671% |
| Cronos Group Inc. | 30.33 Million USD | 99.162% |
| OptiNose, Inc. | 8.05 Million USD | 96.841% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -25435100.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | 95.537% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 99.1% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | 90.499% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | 94.482% |
| Radius Health, Inc. | 278.64 Million USD | 99.909% |
| Universe Pharmaceuticals INC | 3.34 Million USD | 92.392% |
| ProPhase Labs, Inc. | 3.84 Million USD | 93.378% |
| Phibro Animal Health Corporation | 265.91 Million USD | 99.904% |
| Procaps Group S.A. | 96.83 Million USD | 99.737% |
| Alvotech | 74.43 Million USD | 99.658% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 99.993% |
| Rockwell Medical, Inc. | 5.87 Million USD | 95.668% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 97.987% |
| SIGA Technologies, Inc. | 64.21 Million USD | 99.604% |
| Tilray Brands, Inc. | 252.08 Million USD | 99.899% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 99.364% |
| Shineco, Inc. | 1.58 Million USD | 83.988% |
| PetIQ, Inc. | 159.3 Million USD | 99.84% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 266.485% |
| Incannex Healthcare Limited | -10.01 Million USD | 102.54% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 99.336% |
| Alimera Sciences, Inc. | 1.87 Million USD | 86.463% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 99.325% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | 84.206% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | 94.326% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | 97.55% |
| Hempacco Co., Inc. | 2.54 Million USD | 89.996% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 99.658% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 99.468% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 99.603% |
| Currenc Group, Inc. | 732.91 Thousand USD | 65.296% |
| Kamada Ltd. | 87.74 Million USD | 99.71% |
| Indivior PLC | 141.79 Million USD | 99.821% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | 47.212% |
| Flora Growth Corp. | 8.5 Million USD | 97.01% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | 0.0% |
| Evolus, Inc. | 10.99 Million USD | 97.687% |
| HUTCHMED (China) Limited | 50.25 Million USD | 99.494% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 99.76% |
| Akanda Corp. | 1.28 Million USD | 80.235% |